Journal of the Egyptian National Cancer Institute

Table 2 Factors affecting grade 3–4 oral mucositis

From: Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis

	Number of patients (n)	Grade 3–4 mucositis (n, %)	Univariate p value
Arm
Cisplatin	260	145 (55.8%)	0.012
Cisplatin-nimotuzumab	264	176 (66.7%)	0.012
Gender
Male	445	275 (61.8%)	0.616
Female	79	46 (58.2%)	0.616
ECOG PS
PS 0	116	68 (58.6%)	0.519
PS 1–2	408	253 (62%)	0.519
Stage
III	163	98 (60.1%)	0.771
IV	361	223 (61.8%)	0.771
Radiotherapy technique
Conventional	458	279 (60.9%)	0.787
IMRT	66	42 (63.6%)	0.787
Age (continuous variable)
Age	536	–	–

ECOG-PS Eastern Cooperative Oncology Group performance score, IMRT intensity-modulated radiation therapy

Back to article page